US-based diagnostics company Sherlock Biosciences has announced the acquisition of Sense Biodetection, a global molecular diagnostics innovator with headquarters in Oxford.
The acquisition accelerates Sherlock’s go-to-market strategy by adding Sense’s Veros instrument-free rapid molecular test platform (pictured above) and manufacturing capabilities. Terms of the acquisition are not being disclosed.
“This acquisition accelerates Sherlock’s ability to put the most advanced CRISPR-based diagnostics conveniently in the hands of global consumers,” said Bryan Dechairo, President and CEO of Sherlock Biosciences. “The Sense team has done a great job developing and validating its instrument-free diagnostic technology. Together, we can significantly push forward our go-to-market strategy by leveraging Sense’s innovative chemistry and device engineering, combined with our industry-leading molecular technologies to realise our collective vision of democratising and decentralising diagnostics.”
Sense received its CE Mark in March 2022 for its Veros COVID-19 rapid, instrument-free molecular test, demonstrating strong clinical performance with high sensitivity and specificity. Coupled with Sherlock’s proprietary engineering biology tools, including the first FDA-authorised use of CRISPR technology, this transaction enables Sherlock to bring highly accurate, advanced, handheld tests to global consumers for a wide range of diseases from respiratory and sexual health to global health outbreak response. Sherlock will integrate Sense’s chemistry, manufacturing and technology into its platform, leveraging the company’s proven development and regulatory experience to expand the capabilities of the Sherlock platform and drive further innovation.
“This is a powerful combination of proprietary and leading technologies and will allow Sense to realize our vision of delivering the future of diagnostic testing to transform healthcare,” said Timothy Still, CEO of Sense. “Joining Sherlock with their novel CRISPR technology was an excellent opportunity and we look forward to advancing our platform to meet the need for testing wherever and whenever it is needed.”
Sense is headquartered in Oxford, UK with facilities in Cambridge UK and Milford, MA. Sense launched its first product, Veros COVID-19, in select European and South American markets, and is actively developing a portfolio of tests for other infectious diseases, complementing Sherlock’s mission to develop diagnostic products that improve human health.